Smith & Nephew PLC
LSE:SN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Smith & Nephew PLC
LSE:SN
|
UK |
|
Kron Telekomunikasyon Hizmetleri AS
IST:KRONT.E
|
TR |
|
C
|
China Gas Holdings Ltd
XMUN:EBZ
|
HK |
|
E
|
Evoke Pharma Inc
F:EV0
|
US |
|
C
|
Celcuity Inc
NASDAQ:CELC
|
US |
|
R
|
Rosbank PAO
MOEX:ROSB
|
RU |
Intrinsic Value
Is SN undervalued or overvalued?
See the intrinsic value estimate for Smith & Nephew PLC and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
SN looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with SN’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Smith & Nephew Does
Smith & Nephew makes medical devices that help doctors repair joints, treat wounds, and perform sports medicine and surgical procedures. Its main products include knee and hip implants, arthroscopy tools, wound care dressings, and equipment used in operating rooms and clinics. The company sells mainly to hospitals, surgeons, and other healthcare providers.
- Headquarters
- United Kingdom UK
- Employees
- 16 988
- IPO date
- Aug 13, 1951
Smith & Nephew has no economic moat
Hospitals and clinicians have alternatives in each of Smith+Nephew’s major product areas, from orthopedic devices and sports medicine to wound care. Its products do not become more useful just because more customers use them, and its markets are not limited to one or two suppliers, leaving rivals room to compete for customers.
Read the full moat analysis
Earnings Waterfall
Smith & Nephew PLC
The intrinsic value for Smith & Nephew PLC (SN) under the Base Case is hidden GBX.
Compared with the current market price of 1 122.5 GBX, the stock appears hidden.